Tom Powles (@tompowles1) 's Twitter Profile
Tom Powles

@tompowles1

Interested in Urology Cancers, biomarkers and drug development.

ID: 1206580727296544769

calendar_today16-12-2019 14:24:22

1,1K Tweet

12,12K Followers

62 Following

Tom Powles (@tompowles1) 's Twitter Profile Photo
Tom Powles
@tompowles1

2 years ago

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023